Marius Lund-Iversen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marius Lund-Iversen has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Aasmund Berner
Department of Pathology
1 shared publication- Bjørn Henning Grønberg
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
1 shared publication Erik H. Strøm
Department of Pathology, Oslo University Hospital, Oslo, Norway
1 shared publicationEva Sigstad
1 shared publicationGitta Erika Turowski
1 shared publicationGuro Horni Gløersen
1 shared publication
Latest Publications
- Open Access
- 9 October 2023
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 143 (15)
Milliardprosjekt i Helse Sør-Øst på ville veier
09.10.2023: Debatt - Helse Sør-Øst innfører et kostbart IT-system, mot patologenes råd.
- 9 October 2023
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 143 (15)
Open AccessMilliardprosjekt i Helse Sør-Øst på ville veier
09.10.2023: Debatt - Helse Sør-Øst innfører et kostbart IT-system, mot patologenes råd.
- 28 March 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38 (4) , 2261-2269
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer
Background/Aim: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue. Materials and Methods: Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-α with immunohistochemistry. Results: Biopsies from 222 patients were analyzed. Twenty-three percent were ER-α positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-α positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003). Conclusion: ER-α is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women.
- 28 March 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38 (4) , 2261-2269
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer
Background/Aim: The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue. Materials and Methods: Archived, formalin fixed, paraffin embedded tumor tissue samples were retrospectively analyzed for nuclear expression of ER-α with immunohistochemistry. Results: Biopsies from 222 patients were analyzed. Twenty-three percent were ER-α positive. Fifty-four percent of the patients were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%) patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine and carboplatin. Females with ER-α positive tumors who received PC had a substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003). Conclusion: ER-α is an independent prognostic factor in advanced NSCLC and might also be a predictive factor for response to pemetrexed/carboplatin in women.
- Open Access
- 9 December 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (23/24) , 2279
Uric acid crystals
- 9 December 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (23/24) , 2279
Open AccessUric acid crystals
- Open Access
- 9 July 2011
- Published by Wiley in Case Reports in Medicine
- Vol. 2011, 1-2
Metastatic Malignant Melanoma Mimicking Benign Breast Cysts
Benign cysts are one of the most common mass-occupying lesions of the breast and are often investigated with triple diagnostic trial (clinical examination, radiology, and cytology). Malignant melanoma is one of medicine's imitators, and metastatic disease can mimic cysts. Thorough investigation of any breast mass is essential to clarify its nature.
- 9 July 2011
- Published by Wiley in Case Reports in Medicine
- Vol. 2011, 1-2
Open AccessMetastatic Malignant Melanoma Mimicking Benign Breast Cysts
Benign cysts are one of the most common mass-occupying lesions of the breast and are often investigated with triple diagnostic trial (clinical examination, radiology, and cytology). Malignant melanoma is one of medicine's imitators, and metastatic disease can mimic cysts. Thorough investigation of any breast mass is essential to clarify its nature.
- Open Access
- 1 January 2011
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 131 (1) , 32
Tumordiagnostikk
- 1 January 2011
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 131 (1) , 32
Open AccessTumordiagnostikk